Hepatic hemangioendothelioma: An update

Mayur Virarkar, Mohammed Saleh, Radwan Diab, Melissa Taggart, Peeyush Bhargava, Priya Bhosale

Research output: Contribution to journalReview articlepeer-review

Abstract

Primary epithelioid hemangioendotheliomas of the liver (EHL) are rare tumors with a low incidence. The molecular background of EHL is still under investigation, with WWTR1-CAMPTA1 mutation may function as a tumor marker. Commonly, this tumor is misdiagnosed with angiosarcoma, cholangiocarcinomas, metastatic carcinoma, and hepatocellular carcinoma (sclerosing variant). Characteristic features on imaging modalities such as ultrasound, computed tomography, magnetic resonance imaging and positron emission tomography/computed tomography guide in diagnosis and staging. The "halo sign" and the "lollipop sign" on computed tomography and magnetic resonance imaging are described in the literature. Currently, there are no standardized guidelines for treating EHL with treatment options are broad including: chemotherapy, ablation, surgery and liver transplantation with inconsistent results.

Original languageEnglish (US)
Pages (from-to)248-256
Number of pages9
JournalWorld Journal of Gastrointestinal Oncology
Volume12
Issue number3
DOIs
StatePublished - 2020

Keywords

  • Angiosarcoma
  • Cholangiocarcinomas
  • Epithelioid hemangioendotheliomas
  • Halo sign
  • Hepatocellular carcinoma
  • Lollipop sign

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Hepatic hemangioendothelioma: An update'. Together they form a unique fingerprint.

Cite this